Fortress Biotech, Inc. (FBIO) stock
Close on Nov 11, 2026Market cap $73.92MP/E –Yield –
Fortress Biotech, Inc. grew revenue 15.5% to $68.47M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $73.92M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $73.92M
- P/E ratio
- –
- Price to sales
- 1.08
- Price to book
- 0.45
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $68.47M
- Net income
- $111.82M
- EPS, diluted
- -$0.07
- Book value per share
- $5.16
- Diluted shares
- 32M
Trading
- Next earnings
- Nov 13, 2026 (estimated, before the open)
- Previous close
- $1.91
- Open
- $1.94
- Day's range
- $1.93 – $2.04
- Volume
- 382,208
- Average volume (20 days)
- 205,059
- Beta (5 years)
- 1.38
- 52-week range
- $1.79 – $4.53
- RSI (14 days)
- 50.2
- Volatility (1 year)
- 64.0%
- Relative volume
- 0.90×
- WACC
- 12.6%
On 2 of our idea lists: Net-nets, More cash than they're worth
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | FBIO | S&P 500 | Difference | FBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.9% | -2.4% | −3.4 pts | ||
| 3 months | -23.0% | -1.2% | −21.8 pts | ||
| Year to date | -45.1% | +12.3% | −57.4 pts | ||
| 1 year | -25.0% | +12.4% | −37.4 pts | ||
| 3 years | +53.4% | +78.8% | −25.4 pts | +15.3% | +21.4% |
| 5 years | -96.2% | +75.2% | −171.4 pts | -48.0% | +11.9% |
| 10 years | -95.1% | +311.1% | −406.2 pts | -26.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Fortress Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- News
About Fortress Biotech
Pharmaceutical Preparations
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical assets and product candidates. The company operates primarily through public partner companies and private subsidiaries, which collaborate with academic institutions and pharmaceutical partners. Its commercial offerings focus on branded dermatology therapies, including Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, and other topical treatments for conditions such as rosacea, severe acne, and primary axillary hyperhidrosis. Fortress also advances a clinical and preclinical pipeline spanning oncology, viral infections, rare pediatric genetic disorders, and acute pain.
Company profile, executives and historyFortress Biotech stock: common questions
What is Fortress Biotech's stock price?
FBIO closed at $2.01 on Nov 11, 2026, up 5.24% on the day. Over the past 52 weeks it traded between $1.79 and $4.53.
What is Fortress Biotech's market cap?
Fortress Biotech was worth $73.92M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is FBIO's P/E ratio?
Fortress Biotech lost money over fiscal 2025 (diluted EPS -$0.07), so it has no meaningful P/E ratio.
How much revenue does Fortress Biotech make?
Fortress Biotech reported revenue of $68.47M for the twelve months to Jun 30, 2026, up 15.5% from a year earlier.
Does Fortress Biotech pay a dividend?
No. Fortress Biotech has not paid a cash dividend over the last twelve months.
When does Fortress Biotech report earnings next?
Fortress Biotech is expected to report Q3 FY2026 results on Nov 13, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has FBIO stock performed over the past year?
Including dividends, FBIO returned -25.0% over the past year, against +12.4% for the S&P 500.
Who are Fortress Biotech's competitors?
Companies most similar to Fortress Biotech by business, industry and size include DERM, BFRI, VRCA, ENTA, VRDN.
See a number that looks wrong?